Lovaza® and Microvascular Function in Type 2 Diabetes

• ClinicalTrials.gov Identifier: NCT00931879
• Recruitment Status: Completed
• First Posted: July 2, 2009
• Results First Posted: May 9, 2017
• Last Update Posted: May 9, 2017
• Sponsor: Eastern Virginia Medical School
• Collaborator: GlaxoSmithKline
• Information provided by (Responsible Party): Aaron I. Vinik, MD, PhD, Eastern Virginia Medical School

Study Description

Brief Summary:

The objective of this study is to determine the efficacy of 6 months of 4 g/day oral Lovaza® on endothelial-dependent and heat-induced vasodilation in type 2 diabetics with neuropathy and elevated triglyceride levels. Omega-3 fatty acids appear to exert beneficial effects on vascular function that are independent of the changes in serum triglycerides. The efficacy will be compared with a placebo given at the same duration. Efficacy of the drug will be evaluated after 3 and 6 months of treatment. This timeline should be adequate for evaluation of the primary neurophysiological endpoints. Previously, the investigators have demonstrated that it is feasible to pharmacologically alter nerve fiber density in as little as 18 weeks and that this correlates with subjective and objective measures of neurovascular function. The investigators are predicting an enhancement of post-ischemic hyperemia of the foot dorsum, where the dilative mechanism is primarily endothelium-dependent and a similar improvement in heat-induced hyperemia.

Condition or disease	Intervention/treatment	Phase
Hypertriglyceridemia; Diabetic Neuropathy	Drug: omega-3-ethyl esters; Drug: Placebo	Phase 4

Detailed Description:

This pilot study is a within-subject repeated measures design. This study will compare the neurophysiological and vascular responses to placebo and treatment with Lovaza® (omega-3-acid ethyl esters, Reliant Pharmaceuticals, Inc.) in subjects with type 2 diabetes, neuropathy, and dyslipidemia.

Lovaza's potential mechanism of action is the inhibition of acyl Coenzyme A:1, 2-diacylglycerol acyltransferase and increased peroxisomal β-oxidation in the liver.

Subjects will be recruited and a baseline of physiological, neurological and hematological profile established for each patient. Forty-four subjects (20 in the active arm, 20 in the placebo arm, and 2 replacements for each arm) will receive 4 g/day Lovaza® tablets or placebo for a period of 6 months. All subjects will receive a physical and neurological exam as well as neurovascular function testing. This includes nerve conduction studies, quantitative sensory testing, quantitative autonomic testing, and skin blood flow testing, which includes, ischemia reperfusion. Lab tests include an insulin resistance profile, hepatic and renal function profiles, lipid profile, C-reactive protein, thyroid stimulating hormone, and fatty acids. Other tests include inflammatory markers such as adiponectin and tumor necrosis factor-α. The study is powered to detect differences in microvascular function after 6 months of Lovaza® and differences in ethnic responses.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 44 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes
• Study Start Date: October 2009
• Actual Primary Completion Date: July 2012
• Actual Study Completion Date: July 2012

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.	Drug: Placebo; Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Active Comparator: omega-3-ethyl esters 4g; Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.	Drug: omega-3-ethyl esters; Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients.; Other Name: Lovaza

Outcome Measures

Primary Outcome Measures :

1. Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude. [ Time Frame: One year ]
   19 participants in each arm( placebo or omega-3-ethyl esters 4g) were analyzed . Conduction velocities and amplitude of the following nerves were compared between each arm: Tibial Nerve Ankle Amplitude, Tibial Nerve Popliteal Amplitude, Median Nerve Wrist Amplitude, Median Nerve Elbow Amplitude, Peroneal Motor Nerve Ankle Amplitude, Peroneal Motor Nerve Below Fibular Amplitude, Peroneal Motor Nerve Above Fibular Amplitude, Sensory Median Nerve Wrist Amplitude, Sensory Ulnar, Sensory Sural Ankle Ampltiude Wrist Ampltiude
2. Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures. [ Time Frame: One year ]
   Quantitative Autonomic Function Tests (QAFTs) were performed. Primarily, power spectral analysis of heart rate variability (HRV) and time- and frequency-domain analyses, including measures of the sympathetic and parasympathetic control of the heart beat (R-R interval), were recorded with deep breathing, Valsalva, and standing from the sitting position maneuvers. Additionally, the sample difference of the beat to beat (NN) intervals and the TSP was calculated as well as the standard deviation of all normal R-R intervals (sdNN).
3. Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds. [ Time Frame: One year ]
   Quantitative Sensory Tests (QSTs), including, cold sensation threshold, cold pain threshold and vibration detection threshold, were used to evaluate peripheral sensory perception.
4. Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds [ Time Frame: One year ]
   Quantitative Sensory Tests (QSTs), including vibration detection threshold, were used to evaluate peripheral sensory perception. Mean represents percent change of total group. Measurements taken at baseline and at one year.
5. Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress. [ Time Frame: One year ]
   Oxidative stress/inflammatory markers (IL1β, IKKβ, TLR4, TNF-α, JNK1, toll-like receptor 2) were assessed through a meal challenge.
6. Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity. [ Time Frame: One Year ]
7. Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency. [ Time Frame: One Year ]
8. Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction [ Time Frame: One Year ]
9. Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot. [ Time Frame: One Year ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Subjects may be males or non-pregnant, non-lactating females age 18-80 years.
2. Subjects must have been diagnosed with type 2 diabetes mellitus according to the current ADA criteria.
3. Triglyceride levels above 149 mg/dL
4. Minimum of 2 years after diagnosis of type 2 diabetes
5. Prior to participation in this study, each subject must sign an informed consent document.

Exclusion Criteria:

1. Presence of type 1 diabetes mellitus (defined as C-peptide < 1 ng/ml or diabetes onset at < 35 years of age in a non-obese patient).
2. Presence of diabetic retinopathy that is more severe than "background" level.
3. Presence of diabetic nephropathy, defined by urine dipstick results greater than 300 mg/100 mL for protein (proteinuria).
4. Presence of clinically significant neuropathy that is clearly of non-diabetic origin, e.g. alcoholic or autoimmune.
5. Bilateral amputation of lower extremities or foot ulcers involving the great toes. Presence of neuroarthropathy (Charcot deformity) is allowable.
6. History of major macrovascular events such as myocardial infarction or stroke.
7. Participation in another clinical trial concurrently or within 30 days prior to entry into this study.
8. The use of ACE-inhibiting agents or angiotensin receptor blockade therapy (ARB) is allowed but must have been stable for at least 30 days prior to study entry and may not change during the course of the study. This is prudent due to their potential effects on blood flow.
9. Patients with moderate or severe hepatic insufficiency or abnormalities of liver function defined as any liver enzymes (aspartate aminotransferase,alanine transaminase, alkaline phosphatase) greater than 3 times the upper limit of normal.
10. Presence of pedal edema.
11. Presence or history of heart failure New York Heart Association Class II or greater.
12. Other serious medical conditions that in the opinion of the investigator, would compromise the subject's participation in the study.
13. Concomitant use of medications known to exacerbate triglyceride levels, such as estrogens.

Contacts and Locations

Locations

United States, Virginia

Strelitz Diabetes Center

Norfolk, Virginia, United States, 23510

Sponsors and Collaborators

Eastern Virginia Medical School

GlaxoSmithKline

Investigators

• Principal Investigator: Aaron I Vinik, MD, PhD; Eastern Virginia Medical School
• Study Director: Henri K Parson, PhD; Eastern Virgina Medical School

More Information

• Responsible Party: Aaron I. Vinik, MD, PhD, Principal Investigator, Eastern Virginia Medical School
• ClinicalTrials.gov Identifier: NCT00931879
• Other Study ID Numbers: LVZ111903
• First Posted: July 2, 2009
• Results First Posted: May 9, 2017
• Last Update Posted: May 9, 2017
• Last Verified: March 2017

Additional relevant MeSH terms:

Diabetic Neuropathies; Hypertriglyceridemia; Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases